Intradetrusor injection of botulinum toxin A in children: a 10-year single centre experience

  • Riyad PeeraullyEmail author
  • Christine Lam
  • Nikita Mediratta
  • Ramnik Patel
  • Alun Williams
  • Manoj Shenoy
  • Nia FraserEmail author
Urology - Original Paper



We evaluated the efficacy and safety outcomes of endoscopic intradetrusor botulinum toxin A (BTA) injections for the treatment of children with neuropathic bladder (NB) and non-neuropathic bladder (NNB) with or without detrusor overactivity in a single centre with a retrospective analysis.


For the period 2006–2015, children who received BTA in our hospital were analysed. They were divided into group 1, those with underlying NB and group 2, those without a clear neuropathic cause of symptoms (NNB). Data are given as percentages or medians (interquartile range).


Over the study period, 52 children (28 boys, 54%) received BTA, 28 in group 1 (54%; 17 (61%) boys) and 24 in group 2 (46%; 11 (46%) boys). Age at first injection was 11.8 (9.5–14.4) years. After initial injection, 40 (77%) reported symptomatic improvement, 17 (43%) becoming dry. There was no significant difference in response to initial injection between groups (p = 0.11). Duration of improvement after first injection was 7 (5.8–14) months. Twenty-five (48%) had further injections, of whom 3 (12%) were initial non-responders. Ongoing improvement was reported in 20 (80%), 11 (44%) of whom were dry. There was no significant difference in overall response to injections between groups (p = 0.11). Of the 11 non-responders, none (0/3) improved after subsequent injection and 3 (27%) subsequently underwent major urological surgery. Of the 40 who responded, 2 (5%) underwent major surgery.


BTA injection produced symptomatic improvement in 77% of our study population, with no significant differences in response between NB and NNB groups. In 95% of those who improved, major urinary tract procedures were avoided during the period studied. None of the initial non-responders improved after subsequent BTA injection. BTA injection is effective and reliable in the management of children with NB and NNB refractory to medical therapy.


Children Urology Botulinum toxin A Overactive bladder Neurogenic bladder 


Compliance with ethical standards

Conflict of interest

The authors have no conflict of interest to declare. No funding source was involved in this study.

Ethical approval

All procedures performed on human participants were in accordance with the ethical standards of the institutional and national research committee and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from the parents of each child prior to all the procedures. All parents were informed about the procedure and off-label status of the BTA therapy.


  1. 1.
    Kask M, Rintala R, Taskinen S (2014) Effect of onabotulinumtoxinA treatment on symptoms and urodynamic findings in pediatric neurogenic bladder. J Pediatr Urol 10:280–283CrossRefGoogle Scholar
  2. 2.
    Dasgupta R, Murphy FL (2009) Botulinum toxin in paediatric urology: a systematic literature review. Pediatr Surg Int 25:19–23CrossRefGoogle Scholar
  3. 3.
    Zeino M, Becker T, Koen M, Berger C, Riccabona M (2012) Long-term follow-up after botulinum toxin A (BTX-A) injection into the detrusor for treatment of neurogenic detrusor hyperactivity in children. Cent Eur J Urol 65:156–161CrossRefGoogle Scholar
  4. 4.
    Uçar M, Akgül AK, Parlak A, Yücel C, Kılıç N, Balkan E (2018) Non-invasive evaluation of botulinum-A toxin treatment efficacy in children with refractory overactive bladder. Int Urol Nephrol 50:1367–1373CrossRefGoogle Scholar
  5. 5.
    Proesmans W (2008) The neurogenic bladder: introducing four contributions. Pediatr Nephrol 23:538–540CrossRefGoogle Scholar
  6. 6.
    Nevéus T, von Gontard A, Hoebeke P, Hjälmås K, Bauer S, Bower W et al (2006) The standardization of terminology of lower urinary tract function in children and adolescents: report from the Standardisation Committee of the International Children’s Continence Society. J Urol 176:314–324CrossRefGoogle Scholar
  7. 7.
    Farhat W, Bägli D, Capolicchio G, O’Reilly S, Merguerian PA, Khoury A et al (2000) The dysfunctional voiding scoring system: quantitative standardization of dysfunctional voiding symptoms in children. J Urol 164:1011–1015CrossRefGoogle Scholar
  8. 8.
    Akbal C, Genc Y, Burgu B, Ozden E, Tekgul S (2005) Dysfunctional voiding and incontinence scoring system: quantitative evaluation of incontinence symptoms in pediatric population. J Urol 173:969–973CrossRefGoogle Scholar
  9. 9.
    Chancellor MB, Elovic E, Esquenazi A, Naumann M, Segal KR, Schiavo G et al (2013) Evidence-based review and assessment of botulinum neurotoxin for the treatment of urologic conditions. Toxicon 67:129–140CrossRefGoogle Scholar
  10. 10.
    Hassouna T, Gleason JM, Lorenzo AJ (2014) Botulinum toxin A’s expanding role in the management of pediatric lower urinary tract dysfunction. Curr Urol Rep 15:426CrossRefGoogle Scholar
  11. 11.
    Larijani FJ, Moghtaderi M, Hajizadeh N, Assadi F (2013) Preventing kidney injury in children with neurogenic bladder dysfunction. Int J Prev Med 4:1359–1364Google Scholar
  12. 12.
    Schurch B, Stöhrer M, Kramer G, Schmid D, Gaul G, Hauri D (2000) Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J Urol 164:692–697CrossRefGoogle Scholar
  13. 13.
    Kajbafzadeh A-M, Moosavi S, Tajik P, Arshadi H, Payabvash S, Salmasi AH et al (2006) Intravesical injection of botulinum toxin type A: management of neuropathic bladder and bowel dysfunction in children with myelomeningocele. Urology 68:1091–1096CrossRefGoogle Scholar
  14. 14.
    Chuang Y-C, Kuo H-C, Chancellor MB (2010) Botulinum toxin for the lower urinary tract. BJU Int 105:1046–1058CrossRefGoogle Scholar
  15. 15.
    Schulte-Baukloh H, Michael T, Schobert J, Stolze T, Knispel HH (2002) Efficacy of botulinum-A toxin in children with detrusor hyperreflexia due to myelomeningocele: preliminary results. Urology 59:325–327CrossRefGoogle Scholar
  16. 16.
    Figueroa V, Romao R, Pippi Salle JL, Koyle MA, Braga LHP, Bägli DJ et al (2014) Single-center experience with botulinum toxin endoscopic detrusor injection for the treatment of congenital neuropathic bladder in children: effect of dose adjustment, multiple injections, and avoidance of reconstructive procedures. J Pediatr Urol 10:368–373CrossRefGoogle Scholar
  17. 17.
    Mangera A, Apostolidis A, Andersson KE, Dasgupta P, Giannantoni A, Roehrborn C et al (2014) An updated systematic review and statistical comparison of standardised mean outcomes for the use of botulinum toxin in the management of lower urinary tract disorders. Eur Urol 65:981–990CrossRefGoogle Scholar
  18. 18.
    Schulte-Baukloh H, Michael T, Stürzebecher B, Knispel HH (2003) Botulinum-A toxin detrusor injection as a novel approach in the treatment of bladder spasticity in children with neurogenic bladder. Eur Urol 44:139–143CrossRefGoogle Scholar
  19. 19.
    Kajbafzadeh A-M, Nikfarjam L, Mahboubi AH, Danat S (2010) Antibody formation following botulinum toxin type A (Dysport) injection in children with intractable bladder hyper-reflexia. Urology 76:233–237CrossRefGoogle Scholar
  20. 20.
    Haferkamp A, Schurch B, Reitz A, Krengel U, Grosse J, Kramer G et al (2004) Lack of ultrastructural detrusor changes following endoscopic injection of botulinum toxin type a in overactive neurogenic bladder. Eur Urol 46:784–791CrossRefGoogle Scholar
  21. 21.
    Gamé X, Mouracade P, Chartier-Kastler E, Viehweger E, Moog R, Amarenco G et al (2009) Botulinum toxin-A (Botox) intradetrusor injections in children with neurogenic detrusor overactivity/neurogenic overactive bladder: a systematic literature review. J Pediatr Urol 5:156–164CrossRefGoogle Scholar
  22. 22.
    Safari S, Jamali S, Habibollahi P, Arshadi H, Nejat F, Kajbafzadeh A-M (2010) Intravesical injections of botulinum toxin type A for management of neuropathic bladder: a comparison of two methods. Urology 76:225–230CrossRefGoogle Scholar
  23. 23.
    Léon P, Jolly C, Binet A, Fiquet C, Vilette C, Lefebvre F et al (2014) Botulinum toxin injections in the management of non-neurogenic overactive bladders in children. J Pediatr Surg 49:1424–1428CrossRefGoogle Scholar
  24. 24.
    Altaweel W, Jednack R, Bilodeau C, Corcos J (2006) Repeated intradetrusor botulinum toxin type A in children with neurogenic bladder due to myelomeningocele. J Urol 175:1102–1105CrossRefGoogle Scholar

Copyright information

© Springer Nature B.V. 2019

Authors and Affiliations

  1. 1.Department of Pediatric UrologyNottingham Children’s Hospital, Queens Medical CentreNottinghamUK

Personalised recommendations